All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1300+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

LumiThera nabs FDA approval for light-based dry AMD therapy
Photobiomodulation, dry age-related macular degeneration - Read more

Regeneron, Sanofi’s Dupixent nabs extended label in Europe for pediatric eosinophilic esophagitis patients
Monoclonal antibody, eosinophilic esophagitis - Read more

THE GOOD
Business Development

Advanz Pharma acquires Atarax and Nootropil rights from UCB
Small molecule, anxiety, nootropic, psycho-organic syndrome - Read more

Acadia Pharmaceuticals sells PRV to undisclosed buyer for $150M
Priority review voucher - Read more

Novovax agrees to pay $123.8M to UK government to end COVID-19 vaccine supply pact obligations, payable over 3 years
Vaccine, COVD-19, supply contract - Read more

THE GOOD
Clinical Trials

Arcus Biosciences’ posts promising Ph3 data for domvanalimab + zimberelimab in specific kind of lung cancer
Monoclonal antibody, lung cancer - Read more

RIBOMIC touts positive interim Ph2a data for umedaptanib pegol in achondroplasia
Oligonucleotide-based aptamer, achondroplasia - Read more

Minghui Pharmaceutical’s “promising” initial P1 data for MHB039A bispecfic in soliid tumors
Bispecific antibody, solid tumor, cancer - Read more

THE GOOD
Earnings & Finances

Novo Nordisk handily beats obesity competitor Eli Lilly with staggering obesity drug Q3 YoY sales increase of 81%
GLP-1, obesity - Read more

PRESENTED BY SIZZLE BIO

1 in 16 are diagnosed with lung cancer.

• Early detection saves lives

• Cizzle Bio’s test is 95% accurate

• You can support a patented solution to improve survival rates

Own Shares in Prevention

^{Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at invest.cizzlebio.com}

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Oxford Vacmedix $3M Series B lead investment from existing investors
Cancer vaccine, lung cancer, prostrate cancer, ovarian cancer - Read more

THE GOOD
Market Reports

Approvals aren’t the end of the story, and these kind of companies (and drug types) have mastered the product launch
Product launches, unmet medical need - Read more

THE GOOD
Mergers & Acquisitions

Huons to acquire controlling stake in PanGen Biotech
CDMO, manufacturing, CHO cell lines - Read more

THE GOOD
Partnerships

Tevogen Bio partners with Microsoft AI & cloud tech to search for HPV treatment, allogeneic T-cell therapies
Cell therapy, human papillomavirus infection, cancer, allogeneic T cell - Read more

Ring Therapeutics partners wth Singapore Eye Research Institute and A*STAR on developing novel eye disease, eye cancer gene therapies
Gene therapy, eye disease, eye cancer, drug discovery, drug development - Read more

Plus Therapeutics, SpectronRx radiotherapy manufacturing partnership, focused on rhenium (186Re) obisbemeda
Radiopharm, leptomeningeal metastases, glioblastoma, cancer, manufacturing - Read more

SolasCure, U. S. Army Institute of Surgical Research collab on chronic wound care tech, reduce chance of infection
Recombinant enzyme, wound infection prevention, hydrogel - Read more

THE GOOD
Politics & Policy

Incoming Trump administration may be a boon to pharma deal-making and M&A
Pharma dealmaking, mergers & acquisitions - Read more [Paywall]

Californians vote in favour of 340B drug discount program spending restriction ballot
340B drug discount, drug pricing - Read more [Paywall]

THE GOOD
Public Health

Coalition of Africa CDC, CEPI, Gavi, UNICEF, WHO allocate roughly 900k mpox vaccine doses for 9 African countries
Vaccine, monkeypox (mpox) - Read more

THE GOOD
Research

Recent publications detail how DNA circles (ecDNA) are involved in many human cancers, both in its development and treatment resistance
DNA circles, cancer - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Tango Therapeutics’ TNG908 absolutely flunks Ph1/2 - program cut and stock sinks 42%
Small molecule, glioblastoma, cancer - Read more

MacroGenics holds off on additional vobramitamab duocarmazine investment as it waits for more data
Antibody-drug conjugate, prostate cancer - Read more

THE BAD
Politics & Policy

Concerns begin bubbling in biotech on how RFK Jr. and allies will impact FDA and regulatory landscape
Regulatory policy, healthcare policy - Read more [Paywall]

THE BAD
Strategic Plans

Novo Nordisk ditches potential kidney disease med ocedurenone (part of $1.3B deal with KBP Biosciences) after Ph3 fail in July
Small molecule, chronic kidney disease - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here